to discuss the standard of care and the potential of Biohaven's KV7 ion channel modulator BHV-7000 (formerly KB-3061) for the treatment of epilepsy.
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Digging into the data on Biohaven's potential epilepsy treatment BHV-7000 (formerly KB-3061) presented at ASENT 2023.
Ticker(s): BHVNWho's the expert?
Institution: Advocate Medical Group
- Currently manages around 40 patients with Duchenne muscular dystrophy.
- Extremely familiar with this recent readout and publicly available data on this gene therapy asset as well the differentiation from Elevidys in terms of mechanism, microdystrophin characteristics, efficacy, vector used and safety.
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
